Quick Answer
Kalaris Therapeutics, Inc. reported Shares Outstanding of 22.90 million shares for fiscal year 2025.
Kalaris Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 22.90M | +1588.4% |
| 2024 | 1.36M | -72.7% |
| 2023 | 4.96M | -94.7% |
| 2022 | 93.09M | +46.5% |
| 2021 | 63.57M | +2.6% |
| 2020 | 61.93M | +2849.5% |
| 2019 | 2.10M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 18.70M | -83.8% | +0.0% |
| June 30, 2025 | 18.70M | -83.8% | +0.0% |
| March 31, 2025 | 18.70M | -83.7% | +1278.8% |
| December 31, 2024 | 1.36M | -98.8% | -98.8% |
| September 30, 2024 | 115.44M | +1.3% | +0.1% |
| June 30, 2024 | 115.31M | +1.4% | +0.4% |
| March 31, 2024 | 114.88M | +23.0% | +0.6% |
| December 31, 2023 | 114.15M | +22.6% | +0.2% |
- Kalaris Therapeutics, Inc. showed an increase of +1588.4% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, Kalaris Therapeutics, Inc.’s shares outstanding has grown by 990.7% (from 2.10 million shares to 22.90 million shares).
- The most recent figure is from Kalaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: